# Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers

> **NCT01217814** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 16 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Sarilumab
- **DRUG:** Placebo
- **DRUG:** Golimumab
- **DRUG:** methotrexate (MTX)
- **DRUG:** Folic/folinic acid

## Key facts

- **NCT ID:** NCT01217814
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Due to delay in the study and the impact on the development timelines, not due to any identified safety concerns
- **Last updated:** 2017-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01217814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01217814, "Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01217814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*